AR061506A1 - 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. - Google Patents
3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer.Info
- Publication number
- AR061506A1 AR061506A1 ARP070102670A ARP070102670A AR061506A1 AR 061506 A1 AR061506 A1 AR 061506A1 AR P070102670 A ARP070102670 A AR P070102670A AR P070102670 A ARP070102670 A AR P070102670A AR 061506 A1 AR061506 A1 AR 061506A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- extraction
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos antitumorales obtenidos de una porífera, de la familia Raspailiidae, género Lithoplocamia, especia lithistoides, y derivados de los mismos, composiciones farmacéuticas que los contienen, su uso en medicamentos para el tratamiento del cáncer y métodos para su extraccion. Reivindicacion 1: Un compuesto de formula general 1 en donde R1 es seleccionado entre hidrogeno, ORa, OCORa, OCOORa, NRaRb, NRaCORb, y NRaC(NRa)NRaRb; cada R2 y R3 son independientemente seleccionados entre hidrogeno, aIquiIo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido; cada R41, R42, R43, R44, R45, R46, R47 y R48 son independientemente seleccionados entre hidrogeno, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido; cada R5, R6, y R7 son independientemente seleccionados entre hidrogeno, CORa, COORa, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido, o R5 y R48 junto con el correspondiente átomo de N y C al que están unidos pueden formar un grupo heterocíclico sustituido o no sustituido; cada Ra y Rb son independientemente seleccionados entre hidrogeno, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido, alquinilo C2-12 sustituido o no sustituido, arilo sustituido o no sustituido y grupo heterocíclico sustituido o no sustituido; y cada línea de puntos representa la presencia opcional de un enlace adicional; o una sal farmacéuticamente aceptable, un derivado, un tautomero, una prodroga o un estereoisomero del mismo. Reivindicacion 22: Un procedimiento para la obtencion de un compuesto segun se define en una cualquiera de las reivindicaciones precedentes, o una sal farmacéuticamente aceptable, un derivado, un tautomero, una prodroga o un estereoisomero del mismo, que comprende las etapas de extraccion y aislamiento a partir de Lithoplocamia lithistoides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380173 | 2006-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061506A1 true AR061506A1 (es) | 2008-09-03 |
Family
ID=38508885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102670A AR061506A1 (es) | 2006-06-16 | 2007-06-19 | 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8324406B2 (es) |
| EP (3) | EP2032551B9 (es) |
| JP (2) | JP5117491B2 (es) |
| KR (1) | KR101474031B1 (es) |
| CN (2) | CN101679340B (es) |
| AR (1) | AR061506A1 (es) |
| AT (1) | ATE522514T1 (es) |
| AU (1) | AU2007259257B8 (es) |
| BR (2) | BRPI0722429A2 (es) |
| CA (1) | CA2654334C (es) |
| CY (1) | CY1112103T1 (es) |
| DK (1) | DK2032551T3 (es) |
| ES (1) | ES2371942T3 (es) |
| HK (1) | HK1130052A1 (es) |
| HR (1) | HRP20110845T1 (es) |
| IL (1) | IL195676A (es) |
| MX (1) | MX2008015754A (es) |
| MY (1) | MY145788A (es) |
| NO (2) | NO341508B1 (es) |
| NZ (1) | NZ573706A (es) |
| PL (1) | PL2032551T3 (es) |
| PT (1) | PT2032551E (es) |
| RS (1) | RS52034B (es) |
| RU (2) | RU2444519C2 (es) |
| SG (1) | SG174830A1 (es) |
| SI (1) | SI2032551T1 (es) |
| TW (2) | TWI373469B (es) |
| UA (1) | UA97369C2 (es) |
| WO (1) | WO2007144423A1 (es) |
| ZA (1) | ZA200810315B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119963C2 (uk) * | 2007-12-20 | 2019-09-10 | Фарма Мар, С.А. | Протипухлинні сполуки |
| KR101590202B1 (ko) | 2008-02-20 | 2016-01-29 | 액테리온 파마슈티칼 리미티드 | 아자트리사이클 항생 화합물 |
| AR070458A1 (es) | 2008-02-22 | 2010-04-07 | Actelion Pharmaceuticals Ltd | Derivados de oxazolidina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de una infeccion bacteriana. |
| AR073774A1 (es) | 2008-10-07 | 2010-12-01 | Actelion Pharmaceuticals Ltd | Compuestos antibioticos oxazolidinona triciclicos |
| TWI436999B (zh) | 2008-10-10 | 2014-05-11 | Actelion Pharmaceuticals Ltd | 唑啶基抗生素 |
| WO2010149688A2 (en) | 2009-06-24 | 2010-12-29 | Pharma Mar, S.A. | Antitumoral compounds |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| CN108467378A (zh) * | 2017-02-23 | 2018-08-31 | 复旦大学 | 一种二氢吡喃酮类化合物及其制备方法和用途 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CN110790737B (zh) * | 2019-11-07 | 2022-07-22 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| EP4419513A1 (en) | 2021-10-22 | 2024-08-28 | Pharma Mar S.A. | Antitumoral compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA938019B (en) * | 1992-11-13 | 1995-04-28 | Upjohn Co | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses |
| JP3684426B2 (ja) * | 1993-11-19 | 2005-08-17 | パーク・デイビス・アンド・カンパニー | プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体 |
| US7446196B2 (en) * | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
-
2007
- 2007-06-15 EP EP07765445A patent/EP2032551B9/en active Active
- 2007-06-15 EP EP11177479A patent/EP2404913A3/en not_active Withdrawn
- 2007-06-15 MX MX2008015754A patent/MX2008015754A/es active IP Right Grant
- 2007-06-15 NZ NZ573706A patent/NZ573706A/en unknown
- 2007-06-15 PL PL07765445T patent/PL2032551T3/pl unknown
- 2007-06-15 RS RS20110495A patent/RS52034B/en unknown
- 2007-06-15 DK DK07765445.7T patent/DK2032551T3/da active
- 2007-06-15 CN CN2007800222645A patent/CN101679340B/zh active Active
- 2007-06-15 RU RU2009101150/04A patent/RU2444519C2/ru active
- 2007-06-15 SG SG2011067998A patent/SG174830A1/en unknown
- 2007-06-15 US US12/304,123 patent/US8324406B2/en active Active
- 2007-06-15 CA CA2654334A patent/CA2654334C/en active Active
- 2007-06-15 KR KR1020097000830A patent/KR101474031B1/ko active IP Right Grant
- 2007-06-15 BR BRPI0722429-0A patent/BRPI0722429A2/pt not_active IP Right Cessation
- 2007-06-15 AT AT07765445T patent/ATE522514T1/de active
- 2007-06-15 UA UAA200900292A patent/UA97369C2/ru unknown
- 2007-06-15 JP JP2009514811A patent/JP5117491B2/ja active Active
- 2007-06-15 BR BRPI0713031A patent/BRPI0713031B8/pt active IP Right Grant
- 2007-06-15 ES ES07765445T patent/ES2371942T3/es active Active
- 2007-06-15 AU AU2007259257A patent/AU2007259257B8/en active Active
- 2007-06-15 MY MYPI20085040A patent/MY145788A/en unknown
- 2007-06-15 SI SI200730781T patent/SI2032551T1/sl unknown
- 2007-06-15 CN CN2011102036625A patent/CN102336730A/zh active Pending
- 2007-06-15 WO PCT/EP2007/055959 patent/WO2007144423A1/en active Application Filing
- 2007-06-15 PT PT07765445T patent/PT2032551E/pt unknown
- 2007-06-15 EP EP11177474A patent/EP2404912A3/en not_active Withdrawn
- 2007-06-19 AR ARP070102670A patent/AR061506A1/es active IP Right Grant
- 2007-06-20 TW TW096122071A patent/TWI373469B/zh active
- 2007-06-20 TW TW100146802A patent/TW201213316A/zh unknown
-
2008
- 2008-12-02 IL IL195676A patent/IL195676A/en active IP Right Grant
- 2008-12-04 ZA ZA2008/10315A patent/ZA200810315B/en unknown
-
2009
- 2009-01-06 NO NO20090054A patent/NO341508B1/no unknown
- 2009-09-03 HK HK09108044.0A patent/HK1130052A1/xx unknown
-
2011
- 2011-06-29 US US13/171,567 patent/US8501968B2/en active Active
- 2011-08-05 RU RU2011133128/04A patent/RU2011133128A/ru not_active Application Discontinuation
- 2011-09-14 NO NO20111248A patent/NO20111248L/no not_active Application Discontinuation
- 2011-10-05 JP JP2011220925A patent/JP2012021023A/ja active Pending
- 2011-11-14 HR HR20110845T patent/HRP20110845T1/hr unknown
- 2011-11-30 CY CY20111101175T patent/CY1112103T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061506A1 (es) | 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. | |
| ES2973442T3 (es) | Moduladores de la vía integrada del estrés | |
| US10954217B2 (en) | Sigma receptor binders | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
| CL2014000363A1 (es) | Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros. | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| NZ704160A (en) | Azaindole derivatives which act as pi3k inhibitors | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| DK1723138T3 (da) | Substituerede benzimidazoler og deres anvendelse til at inducere apoptose | |
| US20200115345A1 (en) | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| US20210323913A1 (en) | Sigma receptor binders | |
| PE20070167A1 (es) | COMPUESTOS 5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDINA COMO INHIBIDORES DE TIROSINA QUINASA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |